FEATURED COMPANIES
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Oral Cancer Therapeutics Market: About this market
The oral cancer therapeutics market analysis considers sales from both targeted therapy and chemotherapy. Our analysis also considers the sales of oral cancer therapeutics in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as encourage additional R&D investments and exploit interactions and technological capabilities will play a significant role in the targeted therapy segment to maintain its market position. Also, our global oral cancer therapeutics market report looks at factors such as increasing incidence and prevalence of oral cancer, increasing risk factors for oral cancer, growing awareness about oral cancer. However, side-effects of chemotherapeutics, adoption of alternative treatment option as first-line therapy, high treatment cost targeted therapies may hamper the growth of the oral cancer therapeutics industry over the forecast period.
Global Oral Cancer Therapeutics Market: Overview
Growing awareness about oral cancer
Several public and private organizations are taking the initiative to increase awareness about oral cancer. These organization aims to raise awareness about the disease to get more mouth cancers diagnosed at an early stage. The organizations educate the mass about the risk factors, and signs and symptoms and encouraging them to discuss this with their dental professionals. CDC continues its effort to promote oral cancer research, surveillance and comprehensive educational sources for healthcare professionals and the public by increasing excise taxes on tobacco and alcohol products to targeted funding for oral cancer prevention program. This will lead to the expansion of the global oral cancer therapeutics market at a CAGR of over 8% during the forecast period.
Development of nanotechnology-based drug delivery systems
Targeted drug delivery systems by nanoparticles are expected to be the most promising multi-functional platform in cancer therapeutics. The emergence of nanoparticles in drug delivery provided solutions to many challenges such as enhanced and effective drug loading, transportation and controlled drug release, and precise targeting of tumor-sites. They also support in the development of toxic-free atmosphere by reducing the quantity of the drug to a concentration at the surrounding area of the targeted site making it more efficient. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global oral cancer therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oral cancer therapeutics manufacturers. These include AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Endo International Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Also, the oral cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The oral cancer therapeutics market analysis considers sales from both targeted therapy and chemotherapy. Our analysis also considers the sales of oral cancer therapeutics in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as encourage additional R&D investments and exploit interactions and technological capabilities will play a significant role in the targeted therapy segment to maintain its market position. Also, our global oral cancer therapeutics market report looks at factors such as increasing incidence and prevalence of oral cancer, increasing risk factors for oral cancer, growing awareness about oral cancer. However, side-effects of chemotherapeutics, adoption of alternative treatment option as first-line therapy, high treatment cost targeted therapies may hamper the growth of the oral cancer therapeutics industry over the forecast period.
Global Oral Cancer Therapeutics Market: Overview
Growing awareness about oral cancer
Several public and private organizations are taking the initiative to increase awareness about oral cancer. These organization aims to raise awareness about the disease to get more mouth cancers diagnosed at an early stage. The organizations educate the mass about the risk factors, and signs and symptoms and encouraging them to discuss this with their dental professionals. CDC continues its effort to promote oral cancer research, surveillance and comprehensive educational sources for healthcare professionals and the public by increasing excise taxes on tobacco and alcohol products to targeted funding for oral cancer prevention program. This will lead to the expansion of the global oral cancer therapeutics market at a CAGR of over 8% during the forecast period.
Development of nanotechnology-based drug delivery systems
Targeted drug delivery systems by nanoparticles are expected to be the most promising multi-functional platform in cancer therapeutics. The emergence of nanoparticles in drug delivery provided solutions to many challenges such as enhanced and effective drug loading, transportation and controlled drug release, and precise targeting of tumor-sites. They also support in the development of toxic-free atmosphere by reducing the quantity of the drug to a concentration at the surrounding area of the targeted site making it more efficient. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global oral cancer therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oral cancer therapeutics manufacturers. These include AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Endo International Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Also, the oral cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapies under development
Exhibit 22: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AstraZeneca Plc - Vendor overview
Exhibit 50: AstraZeneca Plc - Business segments
Exhibit 51: AstraZeneca Plc - Organizational developments
Exhibit 52: AstraZeneca Plc - Geographic focus
Exhibit 53: AstraZeneca Plc - Key offerings
Exhibit 54: AstraZeneca Plc - Key customers
Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 56: Bristol-Myers Squibb Co. - Product segments
Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 59: Bristol-Myers Squibb Co. - Key offerings
Exhibit 60: Bristol-Myers Squibb Co. - Key customers
Exhibit 61: Eli Lilly and Co. - Vendor overview
Exhibit 62: Eli Lilly and Co. - Business segments
Exhibit 63: Eli Lilly and Co. - Organizational developments
Exhibit 64: Eli Lilly and Co. - Geographic focus
Exhibit 65: Eli Lilly and Co. - Segment focus
Exhibit 66: Eli Lilly and Co. - Key offerings
Exhibit 67: Eli Lilly and Co. - Key customers
Exhibit 68: Endo International Plc - Vendor overview
Exhibit 69: Endo International Plc - Business segments
Exhibit 70: Endo International Plc - Organizational developments
Exhibit 71: Endo International Plc - Geographic focus
Exhibit 72: Endo International Plc - Segment focus
Exhibit 73: Endo International Plc - Key offerings
Exhibit 74: Endo International Plc - Key customers
Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 82: Merck & Co. Inc. - Vendor overview
Exhibit 83: Merck & Co. Inc. - Business segments
Exhibit 84: Merck & Co. Inc. - Organizational developments
Exhibit 85: Merck & Co. Inc. - Geographic focus
Exhibit 86: Merck & Co. Inc. - Segment focus
Exhibit 87: Merck & Co. Inc. - Key offerings
Exhibit 88: Merck & Co. Inc. - Key customers
Exhibit 89: Mylan NV - Vendor overview
Exhibit 90: Mylan NV - Product segments
Exhibit 91: Mylan NV - Organizational developments
Exhibit 92: Mylan NV - Geographic focus
Exhibit 93: Mylan NV - Segment focus
Exhibit 94: Mylan NV - Key offerings
Exhibit 95: Mylan NV - Key customers
Exhibit 96: Pfizer Inc. - Vendor overview
Exhibit 97: Pfizer Inc. - Business segments
Exhibit 98: Pfizer Inc. - Organizational developments
Exhibit 99: Pfizer Inc. - Geographic focus
Exhibit 100: Pfizer Inc. - Segment focus
Exhibit 101: Pfizer Inc. - Key offerings
Exhibit 102: Pfizer Inc. - Key customers
Exhibit 103: Sanofi - Vendor overview
Exhibit 104: Sanofi - Business segments
Exhibit 105: Sanofi - Organizational developments
Exhibit 106: Sanofi - Geographic focus
Exhibit 107: Sanofi - Segment focus
Exhibit 108: Sanofi - Key offerings
Exhibit 109: Sanofi - Key customers
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Targeted therapy - Market size and forecast 2018-2023
- Chemotherapy - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Increasing R&D of new drugs
- Development of nanotechnology-based drug delivery systems
- Patient assistance programs
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Mylan NV
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapies under development
Exhibit 22: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AstraZeneca Plc - Vendor overview
Exhibit 50: AstraZeneca Plc - Business segments
Exhibit 51: AstraZeneca Plc - Organizational developments
Exhibit 52: AstraZeneca Plc - Geographic focus
Exhibit 53: AstraZeneca Plc - Key offerings
Exhibit 54: AstraZeneca Plc - Key customers
Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 56: Bristol-Myers Squibb Co. - Product segments
Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 59: Bristol-Myers Squibb Co. - Key offerings
Exhibit 60: Bristol-Myers Squibb Co. - Key customers
Exhibit 61: Eli Lilly and Co. - Vendor overview
Exhibit 62: Eli Lilly and Co. - Business segments
Exhibit 63: Eli Lilly and Co. - Organizational developments
Exhibit 64: Eli Lilly and Co. - Geographic focus
Exhibit 65: Eli Lilly and Co. - Segment focus
Exhibit 66: Eli Lilly and Co. - Key offerings
Exhibit 67: Eli Lilly and Co. - Key customers
Exhibit 68: Endo International Plc - Vendor overview
Exhibit 69: Endo International Plc - Business segments
Exhibit 70: Endo International Plc - Organizational developments
Exhibit 71: Endo International Plc - Geographic focus
Exhibit 72: Endo International Plc - Segment focus
Exhibit 73: Endo International Plc - Key offerings
Exhibit 74: Endo International Plc - Key customers
Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 82: Merck & Co. Inc. - Vendor overview
Exhibit 83: Merck & Co. Inc. - Business segments
Exhibit 84: Merck & Co. Inc. - Organizational developments
Exhibit 85: Merck & Co. Inc. - Geographic focus
Exhibit 86: Merck & Co. Inc. - Segment focus
Exhibit 87: Merck & Co. Inc. - Key offerings
Exhibit 88: Merck & Co. Inc. - Key customers
Exhibit 89: Mylan NV - Vendor overview
Exhibit 90: Mylan NV - Product segments
Exhibit 91: Mylan NV - Organizational developments
Exhibit 92: Mylan NV - Geographic focus
Exhibit 93: Mylan NV - Segment focus
Exhibit 94: Mylan NV - Key offerings
Exhibit 95: Mylan NV - Key customers
Exhibit 96: Pfizer Inc. - Vendor overview
Exhibit 97: Pfizer Inc. - Business segments
Exhibit 98: Pfizer Inc. - Organizational developments
Exhibit 99: Pfizer Inc. - Geographic focus
Exhibit 100: Pfizer Inc. - Segment focus
Exhibit 101: Pfizer Inc. - Key offerings
Exhibit 102: Pfizer Inc. - Key customers
Exhibit 103: Sanofi - Vendor overview
Exhibit 104: Sanofi - Business segments
Exhibit 105: Sanofi - Organizational developments
Exhibit 106: Sanofi - Geographic focus
Exhibit 107: Sanofi - Segment focus
Exhibit 108: Sanofi - Key offerings
Exhibit 109: Sanofi - Key customers
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
The following companies are recognised as the key players in the global oral cancer therapeutics market: AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Endo International Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of nanotechnology-based drug delivery systems.”
According to the report, one of the major drivers for this market is the growing awareness about oral cancer.
Further, the report states that one of the major factors hindering the growth of this market is the high treatment cost targeted therapies.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of nanotechnology-based drug delivery systems.”
According to the report, one of the major drivers for this market is the growing awareness about oral cancer.
Further, the report states that one of the major factors hindering the growth of this market is the high treatment cost targeted therapies.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Mylan NV
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
LOADING...
